Fulcrum Therapeutics (FULC) Competitors $6.89 -0.10 (-1.43%) As of 02:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FULC vs. EWTX, AUPH, CDTX, PAHC, ARDX, TWST, VERA, AVDL, COGT, and SNDXShould you be buying Fulcrum Therapeutics stock or one of its competitors? The main competitors of Fulcrum Therapeutics include Edgewise Therapeutics (EWTX), Aurinia Pharmaceuticals (AUPH), Cidara Therapeutics (CDTX), Phibro Animal Health (PAHC), Ardelyx (ARDX), Twist Bioscience (TWST), Vera Therapeutics (VERA), Avadel Pharmaceuticals (AVDL), Cogent Biosciences (COGT), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical products" industry. Fulcrum Therapeutics vs. Its Competitors Edgewise Therapeutics Aurinia Pharmaceuticals Cidara Therapeutics Phibro Animal Health Ardelyx Twist Bioscience Vera Therapeutics Avadel Pharmaceuticals Cogent Biosciences Syndax Pharmaceuticals Fulcrum Therapeutics (NASDAQ:FULC) and Edgewise Therapeutics (NASDAQ:EWTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings. Is FULC or EWTX more profitable? Edgewise Therapeutics' return on equity of -30.65% beat Fulcrum Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Fulcrum TherapeuticsN/A -31.05% -28.96% Edgewise Therapeutics N/A -30.65%-29.18% Which has more volatility & risk, FULC or EWTX? Fulcrum Therapeutics has a beta of 2.82, suggesting that its stock price is 182% more volatile than the S&P 500. Comparatively, Edgewise Therapeutics has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500. Do insiders and institutionals have more ownership in FULC or EWTX? 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 7.0% of Fulcrum Therapeutics shares are owned by company insiders. Comparatively, 23.2% of Edgewise Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor FULC or EWTX? In the previous week, Edgewise Therapeutics had 3 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 8 mentions for Edgewise Therapeutics and 5 mentions for Fulcrum Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.72 beat Fulcrum Therapeutics' score of 1.66 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulcrum Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Edgewise Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts prefer FULC or EWTX? Fulcrum Therapeutics presently has a consensus price target of $9.60, suggesting a potential upside of 39.33%. Edgewise Therapeutics has a consensus price target of $40.55, suggesting a potential upside of 182.66%. Given Edgewise Therapeutics' higher probable upside, analysts clearly believe Edgewise Therapeutics is more favorable than Fulcrum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fulcrum Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00Edgewise Therapeutics 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.91 Which has preferable earnings and valuation, FULC or EWTX? Fulcrum Therapeutics has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFulcrum Therapeutics$80M4.66-$9.73M-$1.22-5.65Edgewise TherapeuticsN/AN/A-$133.81M-$1.55-9.25 SummaryFulcrum Therapeutics beats Edgewise Therapeutics on 8 of the 14 factors compared between the two stocks. Get Fulcrum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FULC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FULC vs. The Competition Export to ExcelMetricFulcrum TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$371.87M$3.15B$5.81B$10.17BDividend YieldN/A2.32%5.69%4.61%P/E Ratio-5.6421.3774.6226.02Price / Sales4.66294.32466.0690.52Price / CashN/A45.3337.0859.91Price / Book1.539.6212.166.30Net Income-$9.73M-$53.29M$3.29B$270.86M7 Day Performance-10.05%0.35%1.07%3.41%1 Month Performance5.35%8.99%7.38%6.56%1 Year Performance100.29%12.97%63.13%28.27% Fulcrum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FULCFulcrum Therapeutics2.6745 of 5 stars$6.89-1.4%$9.60+39.3%-21.0%$371.87M$80M-5.64100Positive NewsShort Interest ↓EWTXEdgewise Therapeutics2.8043 of 5 stars$14.88-4.4%$40.55+172.5%-12.9%$1.64BN/A-9.6060Positive NewsAUPHAurinia Pharmaceuticals2.9714 of 5 stars$12.30-0.8%$12.00-2.4%+95.7%$1.63B$235.13M28.61300News CoveragePositive NewsCDTXCidara Therapeutics3.3329 of 5 stars$62.15-1.6%$64.14+3.2%+458.3%$1.60B$1.27M-5.5890Positive NewsPAHCPhibro Animal Health4.5322 of 5 stars$39.43-0.1%$28.40-28.0%+101.4%$1.60B$1.30B33.422,475Trending NewsInsider TradeAnalyst RevisionARDXArdelyx4.6439 of 5 stars$6.59+1.1%$11.70+77.5%+12.1%$1.57B$333.61M-28.6590Positive NewsTWSTTwist Bioscience3.987 of 5 stars$26.25+1.9%$49.40+88.2%-42.3%$1.55B$312.97M-18.10990News CoverageVERAVera Therapeutics2.8729 of 5 stars$24.75+2.3%$63.00+154.5%-34.7%$1.54BN/A-6.9140Positive NewsAVDLAvadel Pharmaceuticals2.9105 of 5 stars$15.38-2.4%$20.86+35.6%+16.2%$1.53B$221.08M-512.6770COGTCogent Biosciences2.8754 of 5 stars$12.68-2.8%$20.00+57.7%+19.6%$1.49BN/A-7.1280Positive NewsSNDXSyndax Pharmaceuticals3.9218 of 5 stars$16.33-4.2%$38.89+138.1%-10.6%$1.47B$23.68M-4.20110Analyst Forecast Related Companies and Tools Related Companies EWTX Competitors AUPH Competitors CDTX Competitors PAHC Competitors ARDX Competitors TWST Competitors VERA Competitors AVDL Competitors COGT Competitors SNDX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FULC) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s “Smart Dollar” just went mainstream"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredElon’s new AI play could hand regular Americans a Tesla‑like paydayElon Musk just launched his boldest AI project yet... And if history is any guide — it could make early inv...Behind the Markets | SponsoredOne tiny company just cracked Google’s $19B problemCurrently, a brand-new, all-American factory outside San Antonio is becoming the most significant site in the ...True Market Insiders | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 Bitcoin miner reveals his trading system (free)There are 18,347 cryptocurrencies in the market right now. 99% of them will fail. And trying to pick winner...Crypto Swap Profits | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulcrum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulcrum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FULC Stock Alerts